Brief: Cardiff Oncology - Nms Informs Cardiff Oncology Of Agreement Termination On May 27, 2026
29/05/2026 22:24
BRIEF-Cardiff Oncology - Nms Informs Cardiff Oncology Of Agreement Termination On May 27, 2026 May 29 (Reuters) - Cardiff Oncology Inc CRDF.O:
CARDIFF ONCOLOGY - NMS INFORMS CARDIFF ONCOLOGY OF AGREEMENT TERMINATION ON MAY 27, 2026 - SEC FILING
CARDIFF ONCOLOGY - NMS ALLEGES CARDIFF ONCOLOGY BREACHED AGREEMENT OVER CARDIFF PATENTS INVENTORSHIP - SEC FILING
CARDIFF ONCOLOGY - NMS ALLEGES FAILURE BY CARDIFF ONCOLOGY TO USE COMMERCIALLY REASONABLE EFFORTS FOR ONVANSERTIB - SEC FILING
CARDIFF ONCOLOGY - STATES NMS TERMINATION NOTICE IS INEFFECTIVE AND WILL CONTINUE UNDER AGREEMENT - SEC FILING
Further company coverage: CRDF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiff Oncology
See all newsBrief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering